WASHINGTON: The Federal Trade Commission in June issued civil subpoenas to Johnson and Johnson as part of an investigation of whether contracting practices for its blockbuster rheumatoid arthritis drug, Remicade, violated antitrust laws, the company said in a regulatory filing on Monday.

Shares of the company were trading marginally down at $132.47, after having closed up 1.7% on Monday.